Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pVAXrcPSAv53I
- Development stage
- Phase 2
- Lead developer
- Karolinska Institutet
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
pVAXrcPSAv53I (also known as pVAXrcPSAv53l) is an investigational DNA vaccine developed for the treatment of relapsed prostate cancer. It was created through a collaboration between the Karolinska Institute and Cyto Pulse Sciences, with clinical sponsorship from Uppsala University Hospital. The vaccine utilizes a plasmid DNA construct that encodes a xenogeneic (rhesus) version of the Prostate-Specific Antigen (PSA). The use of a non-human PSA sequence is intended to enhance the immune system's ability to recognize and attack PSA-expressing cancer cells, effectively breaking the body's natural immune tolerance to the human self-antigen. In clinical trials, the vaccine is administered intradermally using the DERMA VAX™ in vivo electroporation system, which facilitates the entry of the DNA into cells to ensure robust expression of the rhPSA protein and subsequent immune activation.
- Other names
- rhPSA DNA vaccine
02
Targets
pMHC (Peptide-MHC complex family)PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on pVAXrcPSAv53I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pVAXrcPSAv53I.